Friday, 21 Feb 2020

You are here

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders.  A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Subjects from the multicenter Veterans Affairs Rheumatoid Arthritis (VARA) registry were included and assessed for the presence of gout and serum urate (sUA) levels. 

From a total of 1,999 RA patients 17% had elevated sUA levels (>6.8 mg/dl) and 6.1% had a diagnosis of gout.

The presence of moderate hyperuricemia (sUA >6.8‐8 mg/dl) was associated with an increased risk of CVD‐related mortality (HR 1.56; 95% CI 1.11‐2.21), but this association was attenuated and became nonsignificant with adjustments for other comorbidities commonly seen with hyperuricemia. There were no associations of baseline sUA with all‐cause mortality.

Thus there is a small subset of RA patients who may have gout or hyperuricemia and such findings should underscore the need to also manage comorbidities that may contribute to cardiovascular risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.